Andrew Stainthorpe, PhD

Read More ›

Read More ›

The FDA has a regulatory function, which is probably best kept without looking at the costs of the medicines. The role is probably best for an independent HTA organization, like NICE. In Europe, the role of the EMA and of the HTA organization are 2 separate things, and that model works very well there. Read More ›

Cost is a societal factor in the provision of medicines. Oncologists should work in the best interests of their patients and provide the treatments that give patients the most benefit, the fewest side effects, and the best chances of survival. Read More ›

Patients should be given information about the benefits and the consequences, the outcomes of the therapies they’re being offered. Read More ›

Read More ›

Read More ›